Want to see IN:KOPRAN full AI Analyst Report?
KOPRAN Stock Chart & Stats
₹152.20
-₹3.64(-1.71%)
At close: 4:00 PM EST
₹152.20
-₹3.64(-1.71%)
Day’s Range― - ―
52-Week Range₹107.00 - ₹295.90
Previous CloseN/A
Volume53.95K
Average Volume (3M)78.58K
Market Cap
₹13.51B
Enterprise Value₹6.66B
Total Cash (Recent Filing)₹6.82M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)51.1
Beta1.45
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.14%
Share Statistics
EPS (TTM)5.17
Shares Outstanding48,326,103
10 Day Avg. Volume26,181
30 Day Avg. Volume78,585
Financial Highlights & Ratios
PEG Ratio-0.61
Price to Book (P/B)0.98
Price to Sales (P/S)0.77
P/FCF Ratio-49.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthThe acceleration in FY2026 indicates strengthening demand across Kopran’s pharmaceutical activities after modest prior-year growth. Continued top-line expansion can improve operating scale, support investment in products and capacity, and reinforce the company’s market position over the next several quarters.
Conservative Balance SheetModerate leverage relative to the equity base gives Kopran financial flexibility to sustain operations and fund measured growth. The upward trend in equity and total assets also suggests a strengthening balance sheet, helping the company absorb business volatility without excessive dependence on borrowing.
Diversified Pharmaceutical PlatformOperating across APIs and finished dosage formulations gives Kopran multiple routes to pharmaceutical revenue rather than relying on a single product format. Exposure to several therapeutic areas and both domestic and international channels can broaden market access and make the business model more resilient.
Bears Say
Persistently Negative Free Cash FlowRepeatedly negative free cash flow indicates that investment requirements or working-capital needs are absorbing operating cash generation. If sustained, this reduces Kopran’s ability to self-fund expansion, dividends, or debt reduction and may increase reliance on external funding for ongoing growth.
Volatile ProfitabilityUneven margins and the FY2026 decline in net income weaken the predictability of Kopran’s earnings power despite revenue growth. Persistent margin instability can limit internal cash generation, make operating results more sensitive to execution, and reduce confidence that higher sales will consistently translate into profit.
Recent Debt IncreaseThe recent increase in total debt adds a developing pressure point to an otherwise moderate leverage profile. Higher borrowings can raise financing obligations and reduce flexibility if cash conversion remains weak, making the company more dependent on maintaining revenue growth and improving profitability.
Kopran Limited News
KOPRAN FAQ
What was Kopran Limited’s price range in the past 12 months?
Kopran Limited lowest stock price was ₹107.00 and its highest was ₹295.90 in the past 12 months.
What is Kopran Limited’s market cap?
Kopran Limited’s market cap is ₹13.51B.
When is Kopran Limited’s upcoming earnings report date?
Kopran Limited’s upcoming earnings report date is Nov 05, 2026 which is in 12 days.
How were Kopran Limited’s earnings last quarter?
Kopran Limited released its earnings results on Aug 07, 2026. The company reported ₹1.388 earnings per share for the quarter.
Is Kopran Limited overvalued?
According to Wall Street analysts Kopran Limited’s price is currently Overvalued.
Does Kopran Limited pay dividends?
Kopran Limited pays a Annually dividend of ₹3 which represents an annual dividend yield of 1.14%. See more information on Kopran Limited dividends here
What is Kopran Limited’s EPS estimate?
Kopran Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kopran Limited have?
Kopran Limited has 48,326,103 shares outstanding.
What happened to Kopran Limited’s price movement after its last earnings report?
Kopran Limited reported an EPS of ₹1.388 in its last earnings report. Following the earnings report the stock price went down -4.727%.
Which hedge fund is a major shareholder of Kopran Limited?
Currently, no hedge funds are holding shares in IN:KOPRAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kopran Limited
Kopran Limited is a fully integrated pharmaceutical entity that manufactures and distributes both active pharmaceutical ingredients (APIs) and finished drug products, serving markets in India and worldwide. Its extensive product portfolio includes a diverse array of dosage formats, such as tablets, capsules, dry powders, suspensions, and injectable solutions. The company's active pharmaceutical ingredients cater to a broad spectrum of therapeutic applications, encompassing macrolides, antibacterials, anticonvulsants, anti-hypertensives, anti-helminthics, antihistamines, anti-acne treatments, anti-infectives, urologicals, anti-thrombotics, antidiabetics, pain management, gastroenterology, and cardiovascular medications. Established in 1958, Kopran Limited maintains its corporate headquarters in Mumbai, India.
Technical Analysis
Cipla Ltd
―
Marksans Pharma Limited
―
NGL Fine-Chem Ltd.
―
Sanofi India Limited
―
SMS Pharmaceuticals Limited
―